...

CCO Treatment Updates

Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Module

Understanding Key Issues in the Treatment of Castrate-Resistant Prostate Cancer

Program Directors: David I. Quinn, MD, PhD, Nicholas J. Vogelzang, MD

Faculty:

David I. Quinn, MD, PhD
  • David I. Quinn, MD, PhD

CREDIT INFORMATION

Release Date: February 20, 2009

Expiration Date: February 19, 2010


Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Status: The activity is not currently available for credit.

Begin the Module

David I. Quinn, MD, PhD, explores current approaches for managing patients with castrate-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define the criteria by which a patient is classified as castrate resistant
  • Describe current treatment approaches for patients with castrate-resistant prostate cancer
  • Explain factors to consider when choosing treatment options for castrate-resistant prostate cancer patients
  • Cite novel research advances and therapeutic treatment options for the treatment of patients with castrate-resistant prostate cancer

Virtual Presentation

Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Faculty:

Nicholas J. Vogelzang, MD
  • Nicholas J. Vogelzang, MD

CREDIT INFORMATION

Release Date: March 16, 2009

Expiration Date: March 15, 2010


Physicians: maximum of 0.75 AMA PRA Category 1 Credits

Status: The activity is not currently available for credit.

Begin the Virtual Presentation

Nicholas J. Vogelzang, MD, reviews the standards of care and emerging novel therapies for the treatment of castrate-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Distinguish criteria to determine when a patient with prostate cancer is castrate resistant
  • Describe the results of clinical trials of bone-targeted agents to treat bone metastases in patients with prostate cancer
  • Compare results of clinical trials of chemotherapies and novel agents for the treatment of prostate cancer
  • Discuss alternative treatment regimens for prostate cancer patients who fail docetaxel
  • Cite patient-specific factors that influence the choice of treatment in the setting of castrate-resistant prostate cancer

Slideset: Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Download the Slideset


Downloadable slideset on the standards of care and emerging novel therapies for the treatment of castrate-resistant prostate cancer.


Format: Microsoft PowerPoint (.ppt) | File size: 1.94 MB | Date posted: 3/16/2009


Interactive Tool

Castrate-Resistant Prostate Cancer Expert Insight Tool

Launch Tool


Use this interactive tool to enter details of a specific patient and see the treatment approach of 7 experts.

This Castrate-Resistant Prostate Cancer interactive decision support tool enables clinicians to get one step closer to recommended treatment choices for consideration for their castrate-resistant patients with just a few clicks through the tool. Step-by-step, it intuitively guides the user through a series of questions of patient criteria and characteristics and based on that input provides treatment options from 7 prostate cancer experts. A graphical view showing how all 7 experts responded to the patient characteristics entered accompanied by detailed, evidence-based background on treatment choices and considerations are also included.

Format: Adobe Flash (.swf) | File size: 173 KB


Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.